ML23017A160
| ML23017A160 | |
| Person / Time | |
|---|---|
| Site: | Hermes File:Kairos Power icon.png |
| Issue date: | 01/10/2023 |
| From: | Benjamin Beasley NRC/NRR/DANU/UAL1 |
| To: | Advisory Committee on Reactor Safeguards |
| References | |
| Download: ML23017A160 (1) | |
Text
16 OTHER LICENSE CONSIDERATIONS THIS NRC STAFF DRAFT SE HAS BEEN PREPARED AND IS BEING RELEASED TO SUPPORT INTERACTIONS WITH THE ACRS. THIS DRAFT SE HAS NOT BEEN SUBJECT TO FULL NRC MANAGEMENT AND LEGAL REVIEWS AND APPROVALS, AND ITS CONTENTS SHOULD NOT BE INTERPRETED AS OFFICIAL AGENCY POSITIONS.
Kairos Power LLC (Kairos) preliminary safety analysis report (PSAR), Revision XX, Chapter 16, Other License Considerations, Section 16.1, Prior Use of Facility Components, states that the Hermes facility will be constructed of new and appropriately qualified structures, systems, and components to conduct operations. Discussions regarding used systems and components are not applicable to the facility. Additionally, in PSAR Section 16.2, Medical Use of Non-Power Reactors, Kairos states that the Hermes facility will not contain equipment or facilities associated with direct medical administration of radioisotopes or other radiation-based therapies and [Kairos] has no plans at this time to support medical uses. Therefore, discussions involving medical use of the facility are not applicable. PSAR Chapter 16 does not identify any other special license considerations that are not discussed elsewhere in the PSAR.
The U.S. Nuclear Regulatory Commission (NRC) staff (the staff) evaluated the descriptions and discussions of the Hermes facility in the PSAR and finds that the preliminary design of the Hermes facility does not include prior use components and that the Hermes facility will not be used for direct medical therapy. Furthermore, the staff did not identify any other special license considerations relevant to Hermes that are not addressed elsewhere in the PSAR and considered in other chapters of this safety evaluation (SE), as appropriate. The staff concludes that an evaluation using the guidelines of NUREG-1537, Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors, Part 2, Standard Review Plan and Acceptance Criteria, Chapter 16, Other License Considerations, is not necessary because:
(1) All equipment to be installed in the Hermes facility will be new and purpose-built. No prior use components will be used in the construction of the reactor or support systems; (2) The Hermes facility will not contain equipment or facilities associated with the direct medical administration of radioisotopes or other radiation-based therapies; and (3) There are no identified license considerations relevant to Hermes that are not considered elsewhere in this SE.
References Kairos Power LLC. Submittal of the Preliminary Safety Analysis Report for the Kairos Power Fluoride Salt-Cooled, High Temperature Non-Power Reactor (Hermes), Revision 1, September 2022, ADAMS No. ML22272A593.
The U. S. Nuclear Regulatory Commission (NRC). NUREG-1537, Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors, Part 2, Standard Review Plan and Acceptance Criteria. NRC: Washington, D.C. February 1996. ADAMS Accession No. ML042430048.